Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. - Wikidata - awgldk - TriplyDB

Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.

Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.

http://www.wikidata.org/entity/Q37653181

about

Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab DOACs - advances and limitations in real world Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review Recent advances in the development of specific antidotes for target-specific oral anticoagulants A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution?Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.Interrupting anticoagulation in patients with nonvalvular atrial fibrillation.A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits.Efficacy and safety of the drugs used to reverse direct oral anticoagulants: a systematic review and meta-analysis.Effect of Catnip Charcoal on the In Vivo Pharmacokinetics of the Main Alkaloids of Rhizoma Coptidis.Strategies for urgent reversal of target-specific oral anticoagulants.Managing bleeding and emergency reversal of newer oral anticoagulants: a review for primary care providers.Antithrombotic treatment and intracerebral haemorrhage: between Scylla and Charybdis.Reversal Strategies for Intracranial Hemorrhages in Patients Taking Oral Factor Xa Inhibitors.Current and developing strategies for monitoring and reversing direct oral anticoagulants in patients with non-valvular atrial fibrillation.How to effectively manage the event of bleeding complications when using anticoagulants.Who, when, and how to reverse non-vitamin K oral anticoagulants.Clinical implications of reversal agents for direct oral anticoagulants.Reversal of Anticoagulation and Management of Bleeding in Patients on Anticoagulants.Novel Oral Anticoagulants in Atrial Fibrillation: Update on Apixaban.Drug Treatment of Venous Thromboembolism in the Elderly.Apixaban: A Review in Venous Thromboembolism.Managing the perioperative patient on direct oral anticoagulants.Clinical implications, benefits and pitfalls of using and reversing non-vitamin K antagonist oral anticoagulants.Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants.Plasma Exchange for Urgent Apixaban Reversal in a Case of Hemorrhagic Tamponade after Pacemaker Implantation.Accidental Rivaroxaban Overdose in a Patient with Pulmonary Embolism: Some Lessons for Managing New Oral Anticoagulants.New horizons in anticoagulation: Direct oral anticoagulants and their implications in oral surgery.Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guidelines.Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.Evaluation of Clopidogrel Conjugation Metabolism: PK Studies in Man and Mice of Clopidogrel Acyl Glucuronide.Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban.Antidotes to non-vitamin K oral anticoagulants: necessary or not?Effect of Activated Charcoal on Rivaroxaban Complex Absorption.Anti-Xa activity in apixaban overdose: a case report.Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa.

P2860

Q26764874-9F7BD1A5-66CD-468D-A145-E6102235A369 Q26764882-97E5D693-F664-4149-9C9D-0996D150E043 Q28070132-FB976F12-3F49-4E3D-BF95-9427243D90C8 Q28081918-4C6E584C-844B-4A85-9A8E-96C80408F614 Q28256340-D407C01D-9679-43EB-BAEE-396073AD3462 Q34109813-729DF8AB-202D-4EFC-8F2F-82E7F6043C32 Q34469002-C9812466-E54F-462D-8DBF-BF7B69EC49D0 Q34688742-50CD710F-CF52-47AA-B32B-25C15414A9A5 Q35986742-943C1283-E178-4D6E-B8A6-5BE17DF5621E Q36321564-D60AAB4E-16ED-4497-8A9C-2DC52C73171F Q36980358-41E105D1-4664-4BAA-A85F-28614AE37510 Q38285105-BA9E73CA-79C8-4614-912F-BCD51FC84B55 Q38287151-5279F1BF-68E5-4964-AAE6-EF204B68C97F Q38448388-DCA89ED7-F5AC-4F9F-8BFC-98AA51172BE7 Q38602484-CF9DD96B-83D0-47B8-B3DB-15817E20F95E Q38631033-1B1FD9BD-ED4B-4FC8-8474-A62DA2610291 Q38634835-9219AA60-C986-4F2D-8E81-BDA9FD229A2B Q38655960-A64C40AF-ACBE-4A6B-903D-4EE6D85B34F1 Q38757405-5C696086-989C-4490-9C02-9D620F379DD9 Q38803293-2455E171-1DE7-4B3B-B14E-EF40A25E9321 Q38838530-65202EDA-BE99-40BC-BD69-EB5E42E6064E Q38851927-62FDE8A9-ECFE-45AD-832E-387FDFBD5432 Q38960858-1669DA8F-900F-43A3-A808-D78533DA480B Q39253985-C83FCF3D-8A8D-4863-98D2-2F867CA08CEA Q39456624-AA783B4F-EE7E-4219-AA05-96DB07CF61F6 Q40081589-F10E1AA8-E29E-48E1-8450-45426A54C852 Q42072098-6374CF70-C62B-46C9-B2C5-30A86E20B37B Q42256340-064FC398-D2C8-498B-940A-80E45DEF3496 Q47099414-FB908C8B-E03F-4135-829A-4E420351F87A Q48248862-A22922FD-C78C-4F3C-A987-809D49BC5A4C Q48599279-CB9FBAA4-E64B-463E-9E7B-9711C8D42152 Q48606651-8BCD8F64-BB34-48FF-B2C5-DC6229C3332A Q48948394-27E9998E-832F-4273-AF9A-45059C8A67A5 Q50963192-67B0E5AD-CBBA-4012-9A61-710B922766D4 Q51032306-A5655D97-66A6-4C54-867F-DEA047552B07 Q51629843-1ADEC2B6-4E8E-4731-B02D-F96A9BCB31ED Q53218072-01F8F16F-2404-4125-9C9D-2BE286D45CE5

P2860

Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.

http://www.wikidata.org/entity/Q37653181

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.

@en

Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.

@nl

type

label

Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.

@en

Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.

@nl

prefLabel

Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.

@en

Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.

@nl

P1433

Q37653181-A75430DB-9EC4-442A-AC92-AC41972B04B8

P1476

Q37653181-0BC1C371-B170-41DB-BA87-64B688AD1C78

P2093

Q37653181-099B31C3-007E-4390-99A7-2C30ECDDE7D5

Q37653181-32AE19D0-171E-41F1-860B-A4F126D3513D

Q37653181-672EAF8E-C1B9-4565-A7C4-364FE753885D

Q37653181-A2607ABF-F88B-4E8F-AD97-E6EB3DC29D92

Q37653181-A560DA1C-B060-4AAC-8176-E4F206B336BC

Q37653181-AE75DFB0-BA53-4767-85B9-3B513CD52324

Q37653181-EB278C72-8C32-4B8C-83C7-500DEB170A63

P2860

Q37653181-06F1D66B-5A33-4E53-A514-1A7B9C416D1F

Q37653181-13FC8D64-3B63-4916-9FD3-875BBE3A7298

Q37653181-37976AD4-DF7D-4E81-89E1-825ABC9E2675

Q37653181-3C33E1EE-E9D6-43F3-B89D-A049BCEF9410

Q37653181-44AD128F-A1C9-44CE-A1A8-911BAAF27BFC

Q37653181-4AA196A3-1AA8-48DA-A1B0-F03FC653B5D9

Q37653181-51D7C368-45B8-4916-AD90-E1F7F7EB0F9D

Q37653181-73C6AB7D-9BEE-46BB-9155-8E680EFE2CE4

Q37653181-8054D1F9-2EC7-4B46-AF54-9313C01A8EDC

Q37653181-8330C3C3-7F51-471E-B182-713F47CFAF53

P2888

Q37653181-82FB71FC-6B08-4A7F-BA87-D16B7933C12C

P304

Q37653181-1C821B09-60E0-408F-A8E0-6529ED3410A1

P31

Q37653181-93C8DE59-81CC-4CA1-B8E2-0D1E90CE9B38

P356

Q37653181-F9A6A974-42BB-4D41-9C7E-376B0300941E

P433

Q37653181-D5BA1BAC-63C4-4609-B2D9-5D5542C4A915

P478

Q37653181-BBE768A3-5545-4FE2-8E8F-C84A32DE17D8

P577

Q37653181-E659F8C9-AE71-4324-86F0-3B9B8EEC117C

P5875

Q37653181-E6680203-4477-45F3-82B4-4B98BAFCC125

P698

Q37653181-8D25E2F1-9917-46F5-A886-C6B9000BD13F

P932

Q37653181-909F5934-249F-416D-8A1F-AC07085439F5

P356

S40256-013-0055-Y

P1433

American journal of cardiovascular drugs

P1476

Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects.

@en

P2093

Charles Frost

http://www.w3.org/2001/XMLSchema#string

Donglu Zhang

http://www.w3.org/2001/XMLSchema#string

Giridhar Tirucherai

http://www.w3.org/2001/XMLSchema#string

Jessie Wang

http://www.w3.org/2001/XMLSchema#string

Rebecca A Boyd

http://www.w3.org/2001/XMLSchema#string

Sabiha Mondal

http://www.w3.org/2001/XMLSchema#string

Xiaoli Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulat

Position paper: Single-dose activated charcoal

Apixaban versus warfarin in patients with atrial fibrillation

Apixaban metabolism and pharmacokinetics after oral administration to humans.

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.

Apixaban in patients with atrial fibrillation.

Effect of administration of activated charcoal and fibre on absorption, excretion and steady state blood levels of digoxin and digitoxin. Evidence for intestinal secretion of the glycosides.

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

Effectiveness of delayed activated charcoal administration in simulated paracetamol (acetaminophen) overdose.

P2888

s40256-013-0055-y

P304

147-154

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40256-013-0055-Y

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258924010

http://www.w3.org/2001/XMLSchema#string

P698

24277644

http://www.w3.org/2001/XMLSchema#string

P932

3961628

http://www.w3.org/2001/XMLSchema#string